Skip to main content

Table 4 Multivariable analysis by Cox regression model

From: Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin

Variable

Number

HR (95% CI)

P-value

ECOG

 0–1

164

1.00

 

 2

9

0.79 (0.34–1.85)

0.586

Invasion to liver

 No

126

1.00

 

 Yes

47

0.91 (0.59–1.39)

0.648

Metastasis to liver

 No

99

1.00

 

 Yes

74

1.63 (1.11–2.40)

0.013

Metastasis to bone and muscle

 No

159

1.00

 

 Yes

14

1.78 (0.93–3.42)

0.081

NLR

  < 3

75

1.00

 

  ≥ 3

98

1.65 (1.09–2.49)

0.017

PLR

  < 190

102

1.00

 

  ≥ 190

71

1.19 (0.79–1.77)

0.405

Total bilirubin

  ≤ 1.5 X ULN

130

1.00

 

  > 1.5 X ULN

43

1.56 (0.95–2.55)

0.077

Transaminase

  ≤ 1.5 X ULN

120

1.00

 

  > 1.5 X ULN

53

0.92 (0.59–1.45)

0.723

CEA, ng/mL

  < 5

103

1.00

 

  ≥ 5

70

1.50 (1.02–2.19)

0.038

CA 19–9, U/mL

  < 500

114

1.00

 

  ≥ 500

59

1.59 (1.01–2.50)

0.043

  1. ECOG Eastern Cooperative Oncology Group, CEA carcinoembryonic antigen, CA 19–9 carbohydrate antigen 19–9, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, CEA carcinoembryonic antigen, CA 19–9 carbohydrate antigen 19–9, ULN upper limit of normal